NovoCure Limited (NVCR)
After hours:
| Previous close | 23.15 |
| Open | 23.24 |
| Bid | 22.31 x 600 |
| Ask | 22.36 x 300 |
| Day's range | 21.64 - 23.52 |
| 52-week range | 10.87 - 82.64 |
| Volume | |
| Avg. volume | 1,387,222 |
| Market cap | 2.402B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.75 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.92 |
Business WireTIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
ROOT, Switzerland, May 23, 2024--Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma (GBM) in Germany. The TIGER study enrolled 429 patients who used TTFields therapy between August 2017 and November 2019 and is the largest prospective, non-interventional study of the use of TTFields therapy in routine c
Insider MonkeyNovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript
NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript May 2, 2024 NovoCure Limited beats earnings expectations. Reported EPS is $-0.36134, expectations were $-0.43. NVCR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. […]
GuruFocus.comNovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported
Comprehensive Analysis of NovoCure's First Quarter Financial Performance
